Is lowering phosphate exposure the key to preventing arterial stiffening with age?

C J Ferro1, C D Chue, R P Steeds

  • 1Department of Nephrology, Queen Elizabeth Hospital, University Hospital Birmingham NHS Foundation Trust, Edgbaston, Birmingham, West Midlands B15 2TH, UK. charles.ferro@uhb.nhs.uk

Insights

High dietary phosphate intake accelerates arteriosclerosis and arterial stiffness, contributing to cardiovascular disease. Reducing phosphate consumption may significantly lower cardiovascular mortality and morbidity.

Area of Science:

  • Cardiovascular science
  • Nephrology
  • Nutritional science

Background:

  • Cardiovascular disease is the leading global cause of death.
  • Arteriosclerosis, characterized by arterial stiffness, contributes significantly to cardiovascular mortality.
  • Serum phosphate is an emerging cardiovascular risk factor implicated in arteriosclerosis and arterial calcification.

Purpose of the Study:

  • To highlight the overlooked role of arteriosclerotic vascular disease in cardiovascular mortality.
  • To explore the link between dietary phosphate, renal function, and arteriosclerosis.
  • To propose phosphate reduction as a strategy to mitigate cardiovascular risk.

Main Methods:

  • This is a viewpoint article, presenting a hypothesis based on existing literature.
  • It reviews the determinants of serum phosphate, including diet and renal function.
  • It discusses the impact of phosphate on arterial stiffness and cardiovascular health.

Main Results:

  • Diets in affluent populations are high in phosphate due to animal protein and preservatives.
  • Ageing populations often have reduced renal function, exacerbating phosphate retention.
  • Phosphate-rich diets, combined with declining kidney function, accelerate arteriosclerosis.

Conclusions:

  • Phosphate-rich diets, especially in individuals with diminished renal function, accelerate arteriosclerosis and arterial stiffness.
  • Reducing dietary phosphate intake is hypothesized to attenuate arterial stiffness progression.
  • This intervention may lead to substantial reductions in cardiovascular mortality and morbidity.

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
Peripheral Artery Disease I: Introduction01:30

Peripheral Artery Disease I: Introduction

Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution01:00

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution

Drug distribution in the human body is influenced by several factors, including plasma protein concentration, body composition, blood flow, tissue-protein concentration, and tissue fluid pH. Among these, changes in plasma protein concentration and body composition due to aging significantly affect how drugs are distributed within the body. Specifically, aging is associated with a decrease in albumin levels by about 10% and an increase in α1-acid glycoprotein levels. These alterations are not...
Pharmacodynamics in Geriatric Patients: Effects of Age01:27

Pharmacodynamics in Geriatric Patients: Effects of Age

Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...